Pharmacokinetics and Pharmacodynamics of a Novel Depot Formulation of Abarelix, a Gonadotropin-Releasing Hormone (GnRH) Antagonist, in Healthy Men Ages 50 to 75

Journal of Clinical Pharmacology

Volumn 44, Issue 5, 2004, Pages 495-502

  Wong, Shekman L ^a   Lau, David T W ^a   Baughman, Sharon A ^a   Fotheringham, Nick ^a   Menchaca, Dora ^a   Garnick, Marc B ^b  

^a AMGEN INC   (United States)

^b Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

Abarelix; Depot formulation; GnRH; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ABARELIX; ANDROSTANOLONE; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BRONCHITIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; EVALUATION; FEVER; GONADOTROPIN RELEASE; HEADACHE; HORMONE INHIBITION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIBIDO DISORDER; MALE; NORMAL HUMAN; PHARMACODYNAMICS; RECEPTOR BLOCKING;

AGED; AGING; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DIHYDROTESTOSTERONE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HALF-LIFE; HUMANS; INJECTIONS, INTRAMUSCULAR; LUTEINIZING HORMONE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OLIGOPEPTIDES; TESTOSTERONE; TIME FACTORS;

EID: 1942476114     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004264920     Document Type: Article

References (11)

1. Fluker MR: Gonadotropin-releasing hormone antagonists. Curr Opin Endocrinol Diabetes 2000;7:350-356.
2. Schally AV: LH-RH analogues: their impact on reproductive medicine. Gynecol Endocrinol 1999;13:401-409.
3. Fluker MR, Monroe SE, Marshall LA, et al: Contrasting effects of a gonadotropin-releasing hormone agonist and antagonist on the secretion of free alpha subunit. Fertil Steril 1994;61:573-575.
4. Garnick MB, Campion M: Abarelix depot, a GnRH antagonist versus LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Mol Urol 2000;4(3):275-277.
5. McLeod D, Zinner N, Tomera K, et al: A phase 3, multiple, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-761.
6. Tomera K, Gleason D, Gittelman M, et al: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165(5):1585-1589.
7. Leroy I, d'Acremont M, Brailly-Tabard S, et al: A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fert Steril 1994;62:461-467.
8. Hall JE, Whitcomb RW, River JE, et al: Differential regulation of luteinizing hormone, follicle stimulating hormone, and the free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists. J Clin Endorinol Metab 1992;75:1220-1225.
9. Wong SL, Lau DT-W, Baughman SA, Menchaca D, Garnick MB: Pharmacokinetics and pharmacodynamics of abarelix, a-gonadotropin releasing hormone (GnRH) antagonist after subcutaneous, continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003;73:304-311.
10. Slayter KL, Ludwig EA, Lew KH, et al: Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1996;59(3):312-321.
11. Duijkers LJM, Klipping C, Willemsen WNP, et al: Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Human Reproduction 1998;13(9):2392-2398.